Zacks Research Weighs in on GSK's Q3 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK - Free Report) - Zacks Research lifted their Q3 2025 EPS estimates for GSK in a note issued to investors on Wednesday, May 21st. Zacks Research analyst E. Bagri now anticipates that the pharmaceutical company will post earnings per share of $1.29 for the quarter, up from their prior forecast of $1.24. The consensus estimate for GSK's current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK's Q1 2026 earnings at $1.10 EPS, Q2 2026 earnings at $1.13 EPS, FY2026 earnings at $4.73 EPS and Q1 2027 earnings at $1.15 EPS.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The firm's revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.43 EPS.

A number of other analysts have also issued reports on the stock. Morgan Stanley assumed coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. BNP Paribas initiated coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price on the stock. Finally, Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $40.58.

GSK Stock Up 2.1%

NYSE GSK traded up $0.84 during mid-day trading on Monday, reaching $40.84. 1,649,052 shares of the company's stock traded hands, compared to its average volume of 4,837,459. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK has a 1-year low of $31.72 and a 1-year high of $45.01. The company has a fifty day simple moving average of $37.29 and a 200-day simple moving average of $36.11. The company has a market cap of $84.27 billion, a price-to-earnings ratio of 25.66, a P/E/G ratio of 1.12 and a beta of 0.51.

Institutional Trading of GSK

Institutional investors and hedge funds have recently made changes to their positions in the stock. HHM Wealth Advisors LLC grew its stake in GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock worth $26,000 after buying an additional 460 shares during the last quarter. Indiana Trust & Investment Management Co boosted its holdings in shares of GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock valued at $25,000 after acquiring an additional 500 shares during the period. Crews Bank & Trust bought a new position in shares of GSK during the fourth quarter worth about $26,000. Costello Asset Management INC acquired a new stake in shares of GSK in the 1st quarter worth about $31,000. Finally, Richardson Financial Services Inc. lifted its position in GSK by 127.9% in the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after purchasing an additional 472 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a $0.4216 dividend. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a yield of 4.13%. The ex-dividend date of this dividend is Friday, May 16th. GSK's payout ratio is presently 86.60%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.